Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study

ConditionHypotension
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age19-40
SponsorSamuel Lunenfeld Research Institute, Mount Sinai Hospital

About this trial

Hypotension is one of the most common adverse effects of spinal anesthesia for cesarean deliveries, affecting as many as 55-90% of mothers. Hypotension during cesarean deliveries can have detrimental effects on the mother and neonate. Various vasopressors, such as ephedrine, phenylephrine and more recently norepinephrine, have been used for the prevention and treatment of hypotension at cesarean deliveries.

Ephedrine was historically considered as the gold standard vasopressor for the management of hypotension during cesarean deliveries. This was based on studies in animal models that showed preserved uteroplacental circulation with ephedrine and not with phenylephrine. However, multiple studies in the past several decades have shown that phenylephrine compared with ephedrine results in a more favorable fetal acid-base status. Consequently, the use of phenylephrine for blood pressure management during cesarean deliveries increased. Recently, norepinephrine was introduced in the obstetrical practice for the management of hypotension at cesarean deliveries, due to its ability to maintain maternal cardiac output better than phenylephrine.

Studies have also investigated the use of vasopressin to limit hypotension during CD. There have been case reports of successful vasopressin usage to treat post-spinal hypotension after CD in patients with advanced idiopathic pulmonary arterial hypertension as well as severe mitral stenosis with pulmonary hypertension. Its effect was associated with hemodynamic stability without evidence of harm to the mother or child. However, much controversy still exists surrounding the choice of vasopressor in the obstetric population, in large part due to their varying efficacies, and maternal and fetal effects.

Vasopressors used for the treatment of hypotension during cesarean deliveries can have significant direct or indirect effects on the perfusion of uteroplacental and umbilical vessels. Reduction of uteroplacental perfusion and constriction of umbilical vessels can result in fetal acidosis, however, the mechanisms for these effects are unclear. The investigators hypothesize that ephedrine, phenylephrine and norepinephrine and vasopressin have variable effects on the contractility of pregnant myometrium and umbilical arteries due to their variable actions on adrenergic alpha (α) and beta (β) receptors, as well as vasopressin1 and vasopressin2 receptors located in these tissues.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients who give written consent to participate in this study

Patients with gestational age 37-41 weeks

Patients of 19-40 years

Non-laboring patients, not exposed to exogenous oxytocin

Disqualifiers

Patients who refuse to give written informed consent

Patients who require general anesthesia

Patients in labor and those receiving oxytocin for induction of labor

Emergency caesarean delivery in labor

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ephedrine

    Drug

    Ephedrine in solution, at applicable concentrations based on literature

  • Phenylephrine

    Drug

    Phenylephrine, at applicable concentrations based on literature

  • Norepinephrine

    Drug

    Norepinephrine, at applicable concentrations based on literature

  • Vasopressin

    Drug

    Vasopressin, at applicable concentrations based on literature

Treatment groups

144 Participants
are divided into 12 treatment groups

12

Treatment groups

See each treatment group below.

Group A: Myometrium + EphedrineExperimental treatment 1 intervention
Group B: Myometrium + PhenylephrineExperimental treatment 1 intervention
Group C: Myometrium + NorepinephrineExperimental treatment 1 intervention
Group D: Myometrium + VasopressinExperimental treatment 1 intervention
Group E: Umbilical artery + EphedrineExperimental treatment 1 intervention
Group F: Umbilical artery + PhenylephrineExperimental treatment 1 intervention
Group G: Umbilical artery + NorepinephrineExperimental treatment 1 intervention
Group H: Umbilical artery + VasopressinExperimental treatment 1 intervention
Group I: Umbilical vein + EphedrineExperimental treatment 1 intervention
Group J: Umbilical vein + PhenylephrineExperimental treatment 1 intervention
Group K: Umbilical vein + NorepinephrineExperimental treatment 1 intervention
Group L: Umbilical vein + VasopressinExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Motility index

Motility index (MI) is a calculated outcome, based on the formula: frequency/(10 x amplitude). Frequency and amplitude are secondary outcome measures as described below. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.

Time frame
4 hours

Secondary outcomes

1

Amplitude of contraction

The maximum extent of uterine muscle and umbilical vessel contractions, measured in grams (g). The analysis is undertaken by attaching myometrial strips and umbilical vessel rings between an isometric force transducer and the base of an organ bath chamber.

Time frame
4 hours
2

Frequency of contraction

The number of contractions in uterine muscle (myometrium) and umbilical vessel rings over 10 minutes, spontaneously and in response to an agonist. The analysis is undertaken by attaching myometrial strips and umbilical vessel rings between an isometric force transducer and the base of an organ bath chamber.

Time frame
4 hours
3

Integrated area under response curve (AUC)

Time frame
4 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.